Presence of serum tripartite motif-containing 21 antibodies in patients with esophageal squamous cell carcinoma
Presence of serum tripartite motif-containing 21 antibodies in patients with esophageal squamous cell carcinoma
复制标题
DOI：
10.1111/j.1349-7006.2006.00192.x
复制
发表时间：
2006-05-01
期刊：
影响因子：
5.7
通讯作者：
Ochiai, T
中科院分区：
文献类型：
--
作者：
Kuboshima, M;Shimada, H;Ochiai, T
SEREX已被应用于食管鳞癌的研究，TRIM 21基因被鉴定为食管鳞癌的SEREX新抗原。使用细菌表达的TRIM 21基因产物通过Western印迹法证实s-TRIM 21-Abs的存在，并评估其在食管SCC患者中的临床病理学意义。在91例食管鳞癌患者中，18例（20%）检测到s-TRIM 21-Ab，但在42例健康供体中未检测到。s-TRIM 21-Abs的存在与肿瘤大小（P = 0.063）和较差的存活率（P = 0.067）部分相关。为了测量血清抗体水平，开发了使用纯化的重组TRIM 21蛋白的ELISA。s-TRIM 21-Abs在食管鳞癌患者中的水平显著高于健康供体（P = 0.013）。s-TRIM 21-Abs可能是诊断和预测食管鳞癌患者疾病进展的有用肿瘤标志物。
SEREX has been applied to esophageal SCC, and the TRIM21 gene was identified as a novel SEREX antigen of esophageal SCC. The presence of s-TRIM21-Abs was confirmed by Western blotting using bacterially expressed TRIM21 gene product and was evaluated for clinicopathological significance in patients with esophageal SCC. s-TRIM21-Abs were detected in 18 (20%) of 91 patients with esophageal SCC but not in 42 healthy donors. The presence of s-TRIM21-Abs was partly associated with tumor size (P = 0.063) and poor survival (P = 0.067). To measure serum antibody levels, ELISA using purified recombinant TRIM21 protein was developed. The levels of s-TRIM21-Abs were significantly higher in patients with esophageal SCC than in healthy donors (P = 0.013). s-TRIM21-Abs may be a useful tumor marker to diagnose and predict disease progression in patients with esophageal SCC.